ASR Vermogensbeheer N.V. Has $36.79 Million Holdings in Johnson & Johnson $JNJ

Key Points

• ASR Vermogensbeheer N.V. increased its investment in Johnson & Johnson by 5.2%, holding a total of $36.79 million in shares.
• Recently, several institutional investors, including Nuveen LLC and Bank of New York Mellon Corp, significantly increased their stakes in Johnson & Johnson.
• Johnson & Johnson reported a net margin of 25% and a year-over-year revenue growth of 5.8%, with earnings per share beating estimates at $2.77.

ASR Vermogensbeheer N.V. raised its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 5.2% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 240,869 shares of the company's stock after buying an additional 12,009 shares during the period. ASR Vermogensbeheer N.V.'s holdings in Johnson & Johnson were worth $36,790,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in JNJ. Nuveen LLC acquired a new position in Johnson & Johnson in the first quarter valued at about $1,369,188,000. Bank of New York Mellon Corp lifted its position in Johnson & Johnson by 26.4% during the 1st quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company's stock worth $3,844,580,000 after buying an additional 4,842,582 shares in the last quarter. Pacer Advisors Inc. lifted its position in Johnson & Johnson by 1,382.0% during the 1st quarter. Pacer Advisors Inc. now owns 3,030,084 shares of the company's stock worth $502,509,000 after buying an additional 2,825,626 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in Johnson & Johnson by 159.6% during the 2nd quarter. Assenagon Asset Management S.A. now owns 4,159,260 shares of the company's stock worth $635,327,000 after buying an additional 2,557,388 shares in the last quarter. Finally, Kingstone Capital Partners Texas LLC acquired a new position in Johnson & Johnson during the 2nd quarter worth about $401,420,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the business's stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.16% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts recently issued reports on JNJ shares. Weiss Ratings reiterated a "hold (c+)" rating on shares of Johnson & Johnson in a research report on Saturday, September 27th. Wells Fargo & Company set a $212.00 price target on Johnson & Johnson and gave the company an "overweight" rating in a research note on Friday. Citigroup upped their price target on Johnson & Johnson from $185.00 to $200.00 and gave the company a "buy" rating in a research note on Thursday, August 21st. Wall Street Zen raised shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Saturday, September 13th. Finally, Erste Group Bank raised shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Wednesday, July 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat, Johnson & Johnson has an average rating of "Moderate Buy" and an average price target of $187.47.

Johnson & Johnson Price Performance

NYSE JNJ opened at $188.51 on Friday. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $189.78. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The firm's 50 day moving average is $176.18 and its 200-day moving average is $162.83. The company has a market capitalization of $453.98 billion, a PE ratio of 20.16, a price-to-earnings-growth ratio of 2.37 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. During the same period last year, the business earned $2.82 earnings per share. The firm's revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were paid a dividend of $1.30 per share. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 2.8%. Johnson & Johnson's payout ratio is currently 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.